MedTrace Logo

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

NCT00982436 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of neoadjuvant chemotherapy (chemotherapy given before radiotherapy) using cisplatin and docetaxel, followed by carboplatin given at the same time as radiotherapy in the treatment of locally advanced head and neck cancer.

Conditions

  • Head and Neck Neoplasms

Interventions

DRUG

Docetaxel/cisplatin

Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles

RADIATION

Radiotherapy

70 Gy in 35 fractions to gross tumor and lymph node metastases

DRUG

Carboplatin

Carboplatin AUC 1.5 intravenous weekly during radiotherapy

Sponsors & Collaborators

  • University of Vermont

    lead OTHER

Principal Investigators

  • Steven M Grunberg, MD · University of Vermont/Feltcher Allen Health Care

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982436 on ClinicalTrials.gov